Slide 1: Full Year Results 30 June 2024
Full Year Results 30 June 2024
Slide 2: Agenda
Agenda 1. Our Purpose & Growth Strategy 2. Business Highlights 3. FY24 Financial Results 4. FY 25 Key Priorities Mick Myers Chief Executive Officer 2
Slide 3: Our Purpose & Growth Strategy
Our Purpose & Growth Strategy 3
Slide 4: Our Purpose & Growth Strategy
Our Purpose & Growth Strategy Refreshed Purpose Strategic Priorities Passionate about making life better Integration of bWellness to deliver increased scale, channel Leading Nutritional & Wellness products to improve your health & wellbeing 1 diversification & synergies for the Nuchev Group What We
Slide 5: Business Highlights
Business Highlights 5
Slide 6: Business Highlights
Business Highlights • Acquisition of bWellness was a highlight in the year – executing our strategy to accelerate our push to breakeven, enabling the Group to build scale, diversification and access the wellness sector with proforma Group sales of $20.6m1 • Oli6® Nutritionals2 sales revenue of $10.9
Slide 7: FY24 Financial Results
FY24 Financial Results 7
Slide 8: FY24 Financial Highlights
FY24 Financial Highlights • Revenue from sales of Oli6® Nutritionals1 for the year ended 30 June 2024 $10.9m (2023: $7.5m) an increase $3.4m or 45% pcp2 • Product mix changes, higher margin products introduced through NPD and savings in warehousing, distribution and logistics costs to deliver a net
Slide 9: FY24 Sales Revenue
FY24 Sales Revenue Sales Revenue1 ($ millions) Significant jump in Oli6® Nutritionals sales1 revenue 12.0 10.9 • Group sales of Oli6® Nutritionals $10.9m up $3.4m or 45% pcp 10.0 • China CBEC sales of Oli6® Nutritionals of $6.1m, and uplift of 7.5 8.0 7.2 6.1 $2.7m or ~80% pcp (2023: $3.4m) 6.0 3.9
Slide 10: FY24 Adjusted EBITDA
FY24 Adjusted EBITDA $ millions FY24 FY23 Significant growth in sales revenue1 1 Oli6 Nutritionals Sales Revenue 10.9 7.5 • Oli6® sales revenue in FY24 increased $3.4m or 45% pcp2 Cost of sales (excluding raw material sales) (7.0) (5.0) Gross Profit 3.9 2.5 Improved gross profit Distribution, wareho
Slide 11: Less cash used in operations
Less cash used in operations Net cash flows used in operations Improved operating results, margins and disciplined Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 working capital management ensured the Group 0 maintained control over cash -500 Adjusted cash used in operations
Slide 12: Balance Sheet
Balance Sheet $ millions 30 Jun 2024 30 June 2023 Cash holding of $7.6m Cash and short-term deposits 7.6 7.5 • Closing cash position in line with FY23 at $7.6m, reflecting the impact of the Trade and other receivables 2.2 0.7 June 2024 equity raise less cash used in operations during the year and ca
Slide 13: Key Priorities in 2025
Key Priorities in 2025 13
Slide 14: Key Priorities in 2025
Key Priorities in 2025 • Integration and improved operational performance of bWellness delivering sales growth, diversification improved cash and positive working capital • Leveraging our strategic distribution agreement with H&S Group to accelerate growth in China CBEC and opening new sales channel
Slide 15: Disclaimer
Disclaimer This presentation is provided by Nuchev Limited (ACN 163 225 090) (Nuchev) to provide summary information about Nuchev and its respective subsidiaries (together, the Group) in relation to a pro-rata non-renounceable entitlement offer of fully paid ordinary shares in Nuchev (New Shares) to
Slide 16: Appendix
Appendix 16
Slide 17: Appendix: Reconciliation of Adjusted EBITDA and cash used in operations
Appendix 1 (a) Reconciliation of operating loss and Adjusted EBITDA: $ millions FY24 FY23 Operating loss per financial statements (7.4) (8.7) Impairment of assets 0.1 0.6 Product Obsolescence & provisioning 0.3 0.6 Depreciation 0.1 0.2 Business combination costs on acquisition 1.0 0.0 Margin on raw
Slide 18: (nuchev’
(nuchev’